Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | Autologous transplant advances: induction and maintenance

Paul Richardson • 18 Mar 2018
EBMT 2018
General Bortezomib CAR-T Carfilzomib Dexamethasone Lenalidomide Melphalan

Autologous stem cell transplantation can prove to be safer in some instances compared with allogeneic transplantation for treating hematological malignancies. Paul Richardson, MD, from the Dana-Farber Cancer Institute, Boston, MA, highlights the importance of administering lenalidomide, bortezomib and dexamethasone (RVd), to maximize efficacy and limit toxicity. Recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

More from Paul Richardson

Mechanistic differences between isatuximab and daratumumab in multiple myeloma
3:09
Mechanistic differences between isatuximab and daratumumab in multiple myeloma
Paul Richardson • 24 Sep 2026
Emerging treatment strategies for extramedullary myeloma
1:46
Emerging treatment strategies for extramedullary myeloma
Paul Richardson • 24 Sep 2026
Evolving role of CELMoDs in multiple myeloma
2:04
Evolving role of CELMoDs in multiple myeloma
Paul Richardson • 24 Sep 2026
Duffy-null genotype and transplant timing in multiple myeloma
3:47
Duffy-null genotype and transplant timing in multiple myeloma
Paul Richardson • 24 Sep 2026

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals